Search Results - "Ogilvie, Brian"

An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides by Kazmi, Faraz, Yerino, Phyllis, McCoy, Chase, Parkinson, Andrew, Buckley, David B., Ogilvie, Brian W.

“…Oligonucleotides represent an expanding class of pharmacotherapeutics in development for various indications. Typically, oligonucleotides are developed with…”
Get full text

Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters by Vermeer, Lydia M M, Isringhausen, Caleb D, Ogilvie, Brian W, Buckley, David B

“…Ketoconazole is a potent CYP3A4/5 inhibitor and, until recently, recommended by the Food and Drug Administration (FDA) and the European Medicines Agency as a…”
Get full text

Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes by Bohl, Christopher, Brouwer, Kenneth, Heyward, Scott, Cottier, Karissa, Noah, Courtney, Ogilvie, Brian

Get full text

The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments by Haupt, Lois J, Kazmi, Faraz, Ogilvie, Brian W, Buckley, David B, Smith, Brian D, Leatherman, Sarah, Paris, Brandy, Parkinson, Oliver, Parkinson, Andrew

“…In the present study, we conducted a retrospective analysis of 343 in vitro experiments to ascertain whether observed (experimentally determined) values of Ki…”
Get full text

Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments by WATANABE, Takao, KUSUHARA, Hiroyuki, ZHUOHAN HU, SUGIYAMA, Yuichi, WATANABE, Tomoko, DEBORI, Yasuyuki, MAEDA, Kazuya, KONDO, Tsunenori, NAKAYAMA, Hideki, HORITA, Shigeru, OGILVIE, Brian W, PARKINSON, Andrew

“…The present study investigated prediction of the overall renal tubular secretion and hepatic clearances of anionic drugs based on in vitro transport studies…”
Get full text

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel by OGILVIE, Brian W, YERINO, Phyllis, KAZMI, Faraz, BUCKLEY, David B, ROSTAMI-HODJEGAN, Amin, PARIS, Brandy L, TOREN, Paul, PARKINSON, Andrew

“…As a direct-acting inhibitor of CYP2C19 in vitro, lansoprazole is more potent than omeprazole and other proton pump inhibitors (PPIs), but lansoprazole does…”
Get full text

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS by OGILVIE, Brian W, DONGLU ZHANG, WENYING LI, RODRIGUES, A. David, GIPSON, Amy E, HOLSAPPLE, Jeff, TOREN, Paul, PARKINSON, Andrew

“…Gemfibrozil more potently inhibits CYP2C9 than CYP2C8 in vitro, and yet the opposite inhibitory potency is observed in the clinic. To investigate this apparent…”
Get full text

In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions by Martin, Parthena, Czerwiński, Maciej, Limaye, Pallavi B., Ogilvie, Brian W., Smith, Steven, Boyd, Brooks

“…Studies support the safety and efficacy of fenfluramine (FFA) as an antiseizure medication (ASM) in Dravet syndrome, Lennox‐Gastaut syndrome, or CDKL5…”
Get full text

System-Dependent Outcomes during the Evaluation of Drug Candidates as Inhibitors of Cytochrome P450 (CYP) and Uridine Diphosphate Glucuronosyltransferase (UGT) Enzymes: Human Hepatocytes versus Liver Microsomes versus Recombinant Enzymes by Parkinson, Andrew, Kazmi, Faraz, Buckley, David B., Yerino, Phyllis, Ogilvie, Brian W., Paris, Brandy L.

“…The ability of a drug to cause clinically significant drug-drug interactions due to direct or metabolism-dependent inhibition of cytochrome P450 (CYP) can…”
Get full text

In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions by Martin, Parthena, Czerwiński, Maciej, Limaye, Pallavi B., Muranjan, Seema, Ogilvie, Brian W., Smith, Steven, Boyd, Brooks

“…Fenfluramine (FFA) has potent antiseizure activity in severe, pharmacoresistant childhood‐onset developmental and epileptic encephalopathies (e.g., Dravet…”
Get full text

An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes by PARKINSON, Andrew, KAZMI, Faraz, BUCKLEY, David B, YERINO, Phyllis, PARIS, Brandy L, HOLSAPPLE, Jeff, TOREN, Paul, OTRADOVEC, Steve M, OGILVIE, Brian W

“…Metabolism-dependent inhibition (MDI) of cytochrome P450 is usually assessed in vitro by examining whether the inhibitory potency of a drug candidate increases…”
Get full text

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist by Ogilvie, Brian W., Torres, Rosarelis, Dressman, Marlene A., Kramer, William G., Baroldi, Paolo

“…Tasimelteon ([1R‐trans]‐N‐[(2‐[2,3‐dihydro‐4‐benzofuranyl] cyclopropyl) methyl] propanamide), a novel dual melatonin receptor agonist that demonstrates…”
Get full text

Effects of monocyte chemoattractant protein‐1, macrophage inflammatory protein‐1α, and interferon‐α2a on P450 enzymes in human hepatocytes in vitro by Czerwiński, Maciej, Gilligan, Krystal, Westland, Kevin, Ogilvie, Brian W.

“…Some immunomodulatory agents stimulate the release of cytokines capable of suppressing P450 enzymes and potentially affecting pharmacokinetics of…”
Get full text

In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran by PARIS, Brandy L, OGILVIE, Brian W, SCHEINKOENIG, Julie A, NDIKUM-MOFFOR, Florence, GIBSON, Remi, PARKINSON, Andrew

“…Milnacipran (Savella) inhibits both norepinephrine and serotonin reuptake and is distinguished by a nearly 3-fold greater potency in inhibiting norepinephrine…”
Get full text

Microsomal cytochrome P450 enzyme activities in nonalcoholic steatohepatitis livers by Czerwinski, Maciej, Oberheide, Brian, Hatfield, Nicholas, Ewy, Bill, Seib, Christopher, Gatineau, Eva, Yiannikouris, Frederique, O’Brien, Molly, Ogilvie, Brian

Get full text

Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4 by HIROUCHI, Masakazu, KUSUHARA, Hiroyuki, ONUKI, Reiko, OGILVIE, Brian W, PARKINSON, Andrew, SUGIYAMA, Yuichi

“…Multidrug resistance-associated protein (MRP) 3/ ABCC3 and MRP4/ ABCC4 are ATP-binding cassette (ABC) transporters expressed in the sinusoidal membrane of…”
Get full text

An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes by NASSAR, Alaa-Eldin F, KING, Ivan, PARKINSON, Andrew, PARIS, Brandy L, HAUPT, Lois, NDIKUM-MOFFOR, Florence, CAMPBELL, Rebecca, USUKI, Etsuko, SKIBBE, Jennifer, BROBST, Dan, OGILVIE, Brian W

“…Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine alkylating (anticancer) agent. Laromustine generates two types of reactive…”
Get full text

The in vitro evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors (ritonavir, clarithromycin and itraconazole) as inhibitors of non-CYP enzymes by Buckley, David B., Ogilvie, Brian W., Yerino, Phyllis

Get full text

Scientific Archives in the Age of Digitization by Ogilvie, Brian

“…Historians are increasingly working with material that is not only digital but has been digitized. Early digitization projects aimed to encode data for…”
Get full text

Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416 by Ye, Christine, Sweeny, David, Sukbuntherng, Juthamas, Zhang, Qingling, Tan, Weiwei, Wong, Simon, Madan, Ajay, Ogilvie, Brian, Parkinson, Andrew, Antonian, Lida

“…SU5416, 3-(3,5-dimethyl-1 H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine…”
Get full text